WS #16367
The biotech sector is seeing positive momentum with Zymeworks entering a global license and collaboration agreement with Roche for its ZW209 trispecific T cell engager. Additionally, AstraZeneca announced statistically significant complete endoscopic remission in a 52-week clinical study for a new drug candidate. These developments provide a defensive growth vector for investors amidst macro volatility.
Biotech Licensing and Clinical Catalysts
The biotech sector is seeing positive momentum with Zymeworks entering a global license and collaboration agreement with Roche for its ZW209 trispecific T cell engager. Additionally, AstraZeneca announced statistically significant complete endoscopic remission in a 52-week clinical study for a new drug candidate. These developments provide a defensive growth vector for investors amidst macro volatility.